sovaldi
Gilead price lambasted by US health insurers
May 21, 2014Medical Communications, Sales and Marketing Gilead, Incivek, Victrelis, hepatitis C, sovaldi
Gilead’s new hepatitis C pill Sovaldi is coming under more pressure in the US as health insurers hit out at …
Europe approves Janssen’s hep C drug Olysio
May 20, 2014Research and Development, Sales and Marketing Janssen, hepatitis C, sovaldi
Janssen-Cilag International’s Olysio has been given marketing authorisation in the European Union for the treatment of adults with hepatitis C …
Sovaldi performs for Gilead
April 24, 2014Sales and Marketing Gilead, HCV, Q1, hepatitis C, sovaldi
Gilead Sciences’ once-daily, oral hepatitis C treatment Sovaldi has returned better than expected figures in the first quarter of the …
Merck gets hep C boost as competition ramps up
April 11, 2014Research and Development, Sales and Marketing Merck, daclatasvir, hep C, sovaldi
Merck has released promising data from a trial which uses two of its investigational compounds to treat patients with hepatitis …
‘Compassionate’ use of hep C combo
February 24, 2014Research and Development, Sales and Marketing CHMP, EMA, Gilead, hep C, ledipasvir, sovaldi
A key adviser to the European regulator has said that Gilead Sciences’ fixed-dose combination of Sovaldi and ledipasvir can be …
Gilead to allow cheaper generics of new hep C drug
February 6, 2014Manufacturing and Production, Sales and Marketing Gilead, India, generics, hep C, s&m, sofosbuvir, sovaldi
Gilead has announced the unusual step of allowing its new and highly expensive hepatitis C pill to be sold as …
Europe nod for Gilead HCV pill
January 20, 2014Sales and Marketing FDA, Gilead, HCV, hep C, sofosbuvir, sovaldi
Gilead Sciences’ once-daily, oral hepatitis C treatment Sovaldi has been given the green light by the European Commission, just a …
Gilead’s $1,000 per day Hep C drug approved
December 9, 2013Sales and Marketing FDA, Gilead, hepc, sofosbuvir, sovaldi
Gilead’s Sovaldi has gained FDA approval as a potential cure for hepatitis C after the US regulator sped up its …
Gilead runs into India patent trouble
November 26, 2013Sales and Marketing Gilead, MSF, hepc, sofosbuvir, sovaldi
Gilead Sciences has run into heavy traffic in India as campaigners attempt to block the company’s patent there on new …
Gilead gets CHMP nod
November 25, 2013Research and Development, Sales and Marketing CHMP, FDA, Gilead, chc, sovaldi
The CHMP has opened the way for Gilead Sciences’ first-in-class investigational chronic hepatitis C drug Sovaldi (sofosbuvir) to get to …
